# US 2025/0084181 A1 · Pertuzumab variants and evaluation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084181 A1
- Document ID: US20250084181A1
- Status: Published application
- Kind: A1
- Application number: 18/914,687
- Filed: 2024-10-14
- Published: 2025-03-13
- Earliest claimed: 2013-04-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Lynn A. Gennaro; Yung-Hsiang Kao; Yonghua Zhang
- Web page: https://patentgrep.com/patent/US20250084181A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 16/30: from tumour cells
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/32: against translation products of oncogenes
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/55: Fab or Fab'
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.

## Claims

### Claim 1

A method for evaluating a Pertuzumab composition comprising: (1) measuring the amount of unpaired cysteine variant in the composition, wherein the unpaired cysteine variant comprises Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab; (2) measuring the amount of afucosylated Pertuzumab in the composition; or (3) measuring the amount of low-molecular-weight-species (LMWS) or high-molecular-weight-species (HMWS) of Pertuzumab in the composition.

### Claim 2 (depends on 1)

The method of claim 1, comprising two or three of (1), (2), and (3).

### Claim 3

A method for evaluating the biological activity of a Pertuzumab composition comprising measuring the amount of afucosylated Pertuzumab variant in the composition to determine the antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the composition, and confirming the amount of afucosylated Pertuzumab is in the range from about 0.9% to about 4.1%.

### Claim 4 (depends on 3)

The method of claim 3, comprising measuring the amount of afucosylated Pertuzumab using capillary electrophoresis-laser-induced fluorescence (CE-LIF).

### Claim 5

A method for making a composition comprising: (1) producing a composition comprising Pertuzumab and one or more variants thereof, and (2) subjecting the composition so-produced to an analytical assay to evaluate the amount of the variant(s) therein, wherein the variant(s) comprise: (i) unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab; (ii) afucosylated variant of Pertuzumab; (iii) high-molecular-weight-species (HMWS) of Pertuzumab; or (iv) low-molecular-weight-species (LMWS) of Pertuzumab.

### Claim 6 (depends on 5)

The method of claim 5, wherein (1) comprises expressing Pertuzumab and the variant(s) from a recombinant Chinese Hamster Ovary (CHO) at manufacturing scale and purifying the composition.

### Claim 7

An isolated variant of Pertuzumab, wherein the isolated variant comprises: (a) an unpaired cysteine variant of Pertuzumab, wherein the variant is a heterodimer variant comprising Cys23/Cys88 unpaired cysteines in only one variable light domain of Pertuzumab; (b) an unpaired cysteine variant of Pertuzumab, wherein the variant is a homodimer variant comprising Cys23/Cys88 unpaired cysteines in both variable light domains of Pertuzumab; (c) afucosylated variant of Pertuzumab; (d) high-molecular-weight-species (HMWS) of Pertuzumab; or (e) low-molecular-weight-species (LMWS) of Pertuzumab.

### Claim 8

A method for evaluating a Pertuzumab composition comprising measuring the amount of Peak 1 fragment and Peak 2 fragment in the composition by reduced capilliary electrophoresis sodium dodecyl sulphate (R-CE-SDS) assay and confirming the amount of Peak 1 fragment is ≤5% and the amount of Peak 2 fragment is ≤1.0%.

### Claim 9

A method for making a composition comprising: (1) producing a composition comprising Pertuzumab and one or more fragments thereof, and (2) subjecting the composition so-produced to an analytical assay to evaluate the amount of Peak 1 fragment and Peak 2 fragment in the composition.
